NASDAQ:CMMB

Chemomab Drops After Board Changes and CEO Stock Purchase
····

Chemomab Drops After Board Changes and CEO Stock Purchase

Chemomab Therapeutics’ shares fell 6.5% to $1.74 on Nasdaq Tuesday after a regulatory filing showed board changes, with Gwen Melincoff joining and two directors resigning. CEO Adi Mor George bought nearly $20,250 in shares last week. Cash stood at $8 million on March 31, enough to fund operations into early 2027. The company is advancing nebokitug for primary sclerosing cholangitis amid rising competition.
June 2, 2026

Stock Market Today

  • SpaceX IPO Sparks Interest for ASX Investors; Betashares ETF and Electro Optic Systems Offer Exposure
    June 2, 2026, 5:55 PM EDT. SpaceX filed for a public offering aiming for a $1.7-$2 trillion valuation, potentially the largest IPO ever. The company reported $18.7 billion revenue in 2025 but remains unprofitable due to high costs. ASX investors cannot buy SpaceX shares directly but can consider Australian options like the Betashares Space Industry ETF (RCKT), which holds key space stocks and has gained 12% since May launch, or Electro Optic Systems Holdings (EOS), known in the defense sector. Inclusion of SpaceX in RCKT depends on index criteria post-listing, which may take months. Both provide risk-weighted exposure to the booming space economy amid SpaceX's anticipated market debut.